-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Lepu Pharmaceuticals was approved for imitating Class 4 sitagliptin phosphate tablets and was deemed to have been over-evaluated
.
According to data from Minet.
com, the global sales of sitagliptin in 2021 will exceed US$3 billion; in recent years, the sales in public medical institutions in China and physical pharmacies in Chinese cities have grown rapidly, with a total of more than 1.
5 billion in 2020
.
.
According to data from Minet.
com, the global sales of sitagliptin in 2021 will exceed US$3 billion; in recent years, the sales in public medical institutions in China and physical pharmacies in Chinese cities have grown rapidly, with a total of more than 1.
5 billion in 2020
.
April 21, 2022 Information release for drug approval documents to be received
The data show that sitagliptin, developed by Merck & Co.
, is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
Compared with traditional hypoglycemic drugs, this class of drugs does not increase the risk of hypoglycemia.
, Neutral impact on body weight, good cardiovascular safety and other advantages
.
In 2021, global sales of sitagliptin will exceed $3 billion
.
, is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
Compared with traditional hypoglycemic drugs, this class of drugs does not increase the risk of hypoglycemia.
, Neutral impact on body weight, good cardiovascular safety and other advantages
.
In 2021, global sales of sitagliptin will exceed $3 billion
.
Sales of sitagliptin phosphate tablets in recent years (unit: 100 million yuan)
Source: Mi intranet database
According to the data of Minet.
com, in recent years, the sales of sitagliptin phosphate tablets in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as China's public medical institutions) terminals and China's urban physical pharmacies have grown rapidly.
In 2020, the total will exceed 1.
5 billion yuan.
Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year growth of more than 30% in the first half of 2021; China's urban physical pharmacy terminals are expected to grow by more than 7% year-on-year in 2021
.
com, in recent years, the sales of sitagliptin phosphate tablets in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as China's public medical institutions) terminals and China's urban physical pharmacies have grown rapidly.
In 2020, the total will exceed 1.
5 billion yuan.
Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year growth of more than 30% in the first half of 2021; China's urban physical pharmacy terminals are expected to grow by more than 7% year-on-year in 2021
.
There are 12 companies with production approvals for sitagliptin phosphate tablets.
Among them, 11 domestic pharmaceutical companies, including Lepu Pharmaceuticals, Nanjing Chia Tai Tianqing Pharmaceuticals, and Sichuan Kelun Pharmaceuticals, have been approved for 4 categories of imitations, which are regarded as over-evaluations
.
More than 10 companies , including Jiangsu Wanbang Biochemical Pharmaceutical , Yantai Luyin Pharmaceutical, and Zhejiang Nuode Pharmaceutical, have submitted their listing applications for review and approval .
It is foreseeable that the competition for this product will be very fierce in the future .
Among them, 11 domestic pharmaceutical companies, including Lepu Pharmaceuticals, Nanjing Chia Tai Tianqing Pharmaceuticals, and Sichuan Kelun Pharmaceuticals, have been approved for 4 categories of imitations, which are regarded as over-evaluations
.
More than 10 companies , including Jiangsu Wanbang Biochemical Pharmaceutical , Yantai Luyin Pharmaceutical, and Zhejiang Nuode Pharmaceutical, have submitted their listing applications for review and approval .
It is foreseeable that the competition for this product will be very fierce in the future .
Prior to this, Lepu Pharmaceuticals had won the compound antihypertensive drug Valsartan Amlodipine Tablets (I), and the total sales of this product in Chinese public medical institutions and Chinese urban physical pharmacies exceeded 2 billion yuan
.
.
Source: State Food and Drug Administration official website, Minet database
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
A few days ago, the official website of the State Food and Drug Administration showed that Lepu Pharmaceuticals was approved for imitating Class 4 sitagliptin phosphate tablets and was deemed to have been over-evaluated
.
According to data from Minet.
com, the global sales of sitagliptin in 2021 will exceed US$3 billion; in recent years, the sales in public medical institutions in China and physical pharmacies in Chinese cities have grown rapidly, with a total of more than 1.
5 billion in 2020
.
.
According to data from Minet.
com, the global sales of sitagliptin in 2021 will exceed US$3 billion; in recent years, the sales in public medical institutions in China and physical pharmacies in Chinese cities have grown rapidly, with a total of more than 1.
5 billion in 2020
.
April 21, 2022 Information release for drug approval documents to be received
The data show that sitagliptin, developed by Merck & Co.
, is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
Compared with traditional hypoglycemic drugs, this class of drugs does not increase the risk of hypoglycemia.
, Neutral impact on body weight, good cardiovascular safety and other advantages
.
In 2021, global sales of sitagliptin will exceed $3 billion
.
, is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
Compared with traditional hypoglycemic drugs, this class of drugs does not increase the risk of hypoglycemia.
, Neutral impact on body weight, good cardiovascular safety and other advantages
.
In 2021, global sales of sitagliptin will exceed $3 billion
.
Sales of sitagliptin phosphate tablets in recent years (unit: 100 million yuan)
Source: Mi intranet database
According to the data of Minet.
com, in recent years, the sales of sitagliptin phosphate tablets in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as China's public medical institutions) terminals and China's urban physical pharmacies have grown rapidly.
In 2020, the total will exceed 1.
5 billion yuan.
Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year growth of more than 30% in the first half of 2021; China's urban physical pharmacy terminals are expected to grow by more than 7% year-on-year in 2021
.
com, in recent years, the sales of sitagliptin phosphate tablets in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as China's public medical institutions) terminals and China's urban physical pharmacies have grown rapidly.
In 2020, the total will exceed 1.
5 billion yuan.
Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year growth of more than 30% in the first half of 2021; China's urban physical pharmacy terminals are expected to grow by more than 7% year-on-year in 2021
.
There are 12 companies with production approvals for sitagliptin phosphate tablets.
Among them, 11 domestic pharmaceutical companies, including Lepu Pharmaceuticals, Nanjing Chia Tai Tianqing Pharmaceuticals, and Sichuan Kelun Pharmaceuticals, have been approved for 4 categories of imitations, which are regarded as over-evaluations
.
More than 10 companies , including Jiangsu Wanbang Biochemical Pharmaceutical , Yantai Luyin Pharmaceutical, and Zhejiang Nuode Pharmaceutical, have submitted their listing applications for review and approval .
It is foreseeable that the competition for this product will be very fierce in the future .
Among them, 11 domestic pharmaceutical companies, including Lepu Pharmaceuticals, Nanjing Chia Tai Tianqing Pharmaceuticals, and Sichuan Kelun Pharmaceuticals, have been approved for 4 categories of imitations, which are regarded as over-evaluations
.
More than 10 companies , including Jiangsu Wanbang Biochemical Pharmaceutical , Yantai Luyin Pharmaceutical, and Zhejiang Nuode Pharmaceutical, have submitted their listing applications for review and approval .
It is foreseeable that the competition for this product will be very fierce in the future .
Prior to this, Lepu Pharmaceuticals had won the compound antihypertensive drug Valsartan Amlodipine Tablets (I), and the total sales of this product in Chinese public medical institutions and Chinese urban physical pharmacies exceeded 2 billion yuan
.
.
Source: State Food and Drug Administration official website, Minet database
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
A few days ago, the official website of the State Food and Drug Administration showed that Lepu Pharmaceuticals was approved for imitating Class 4 sitagliptin phosphate tablets and was deemed to have been over-evaluated
.
According to data from Minet.
com, the global sales of sitagliptin in 2021 will exceed US$3 billion; in recent years, the sales in public medical institutions in China and physical pharmacies in Chinese cities have grown rapidly, with a total of more than 1.
5 billion in 2020
.
.
According to data from Minet.
com, the global sales of sitagliptin in 2021 will exceed US$3 billion; in recent years, the sales in public medical institutions in China and physical pharmacies in Chinese cities have grown rapidly, with a total of more than 1.
5 billion in 2020
.
April 21, 2022 Information release for drug approval documents to be received
The data show that sitagliptin, developed by Merck & Co.
, is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
Compared with traditional hypoglycemic drugs, this class of drugs does not increase the risk of hypoglycemia.
, Neutral impact on body weight, good cardiovascular safety and other advantages
.
In 2021, global sales of sitagliptin will exceed $3 billion
.
, is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
Compared with traditional hypoglycemic drugs, this class of drugs does not increase the risk of hypoglycemia.
, Neutral impact on body weight, good cardiovascular safety and other advantages
.
In 2021, global sales of sitagliptin will exceed $3 billion
.
Sales of sitagliptin phosphate tablets in recent years (unit: 100 million yuan)
Source: Mi intranet database
According to the data of Minet.
com, in recent years, the sales of sitagliptin phosphate tablets in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as China's public medical institutions) terminals and China's urban physical pharmacies have grown rapidly.
In 2020, the total will exceed 1.
5 billion yuan.
Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year growth of more than 30% in the first half of 2021; China's urban physical pharmacy terminals are expected to grow by more than 7% year-on-year in 2021
.
hospital hospital pharmacy pharmacycom, in recent years, the sales of sitagliptin phosphate tablets in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as China's public medical institutions) terminals and China's urban physical pharmacies have grown rapidly.
In 2020, the total will exceed 1.
5 billion yuan.
Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year growth of more than 30% in the first half of 2021; China's urban physical pharmacy terminals are expected to grow by more than 7% year-on-year in 2021
.
There are 12 companies with production approvals for sitagliptin phosphate tablets.
Among them, 11 domestic pharmaceutical companies, including Lepu Pharmaceuticals, Nanjing Chia Tai Tianqing Pharmaceuticals, and Sichuan Kelun Pharmaceuticals, have been approved for 4 categories of imitations, which are regarded as over-evaluations
.
More than 10 companies , including Jiangsu Wanbang Biochemical Pharmaceutical , Yantai Luyin Pharmaceutical, and Zhejiang Nuode Pharmaceutical, have submitted their listing applications for review and approval .
It is foreseeable that the competition for this product will be very fierce in the future .
Pharmaceutical and pharmaceutical enterprisesAmong them, 11 domestic pharmaceutical companies, including Lepu Pharmaceuticals, Nanjing Chia Tai Tianqing Pharmaceuticals, and Sichuan Kelun Pharmaceuticals, have been approved for 4 categories of imitations, which are regarded as over-evaluations
.
More than 10 companies , including Jiangsu Wanbang Biochemical Pharmaceutical , Yantai Luyin Pharmaceutical, and Zhejiang Nuode Pharmaceutical, have submitted their listing applications for review and approval .
It is foreseeable that the competition for this product will be very fierce in the future .
Prior to this, Lepu Pharmaceuticals had won the compound antihypertensive drug Valsartan Amlodipine Tablets (I), and the total sales of this product in Chinese public medical institutions and Chinese urban physical pharmacies exceeded 2 billion yuan
.
.
Source: State Food and Drug Administration official website, Minet database
Source: State Food and Drug Administration official website, Minet database Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
